Luwy K Musey

List of Publications by Year
in descending order

26 papers	714 citations	686830 13 h-index	552369 26 g-index
26 all docs	26 docs citations	26 times ranked	688 citing authors

#	Article	IF	Citations
1	Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. Human Vaccines and Immunotherapeutics, 2019, 15, 530-539.	1.4	80
2	Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults. Vaccine, 2014, 32, 2399-2405.	1.7	79
3	Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Vaccine, 2018, 36, 6883-6891.	1.7	79
4	Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults. Vaccine, 2015, 33, 2793-2799.	1.7	55
5	Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects. Journal of Infectious Diseases, 2019, 220, 411-419.	1.9	48
6	A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. Pediatric Infectious Disease Journal, 2020, 39, 763-770.	1.1	41
7	A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine, 2022, 40, 162-172.	1.7	40
8	Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naÃ¯ve adults â‰¥50 years of age. Vaccine, 2018, 36, 6875-6882.	1.7	35
9	Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults â‰¥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Human Vaccines and Immunotherapeutics, 2019, 15, 540-548.	1.4	35
10	Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence. Expert Review of Vaccines, 2021, 20, 243-256.	2.0	33
11	A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection. Journal of Virology, 2019, 93, .	1.5	32
12	Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults agedâ€¯â‰¥50â€¯years: A randomized phase III trial (PNEU-PATH). Vaccine, 2021, 39, 6422-6436.	1.7	25
13	Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV. Aids, 2022, 36, 373-382.	1.0	15
14	Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects. Human Vaccines and Immunotherapeutics, 2016, 12, 2142-2147.	1.4	14
15	Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses. Vaccine, 2016, 34, 3875-3881.	1.7	12
16	Immunogenicity Comparison of a Next Generation Pneumococcal Conjugate Vaccine in Animal Models and Human Infants. Pediatric Infectious Disease Journal, 2020, 39, 70-77.	1.1	10
17	Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature. Expert Review of Vaccines, 2021, 20, 257-267.	2.0	10
18	Sequential administration of Prevnar 13â„¢ and PNEUMOVAXâ„¢ 23 in healthy participants 50 years of age and older. Human Vaccines and Immunotherapeutics, 2021, 17, 2678-2690.	1.4	10

#	Article	IF	Citations
19	Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged â‰¥50 years: a randomized phase 3 trial (PNEU-FLU). Human Vaccines and Immunotherapeutics, 2021, , 1-14.	1.4	10
20	Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5Âyears does not affect the immunogenicity and safety in the Japanese elderly. Human Vaccines and Immunotherapeutics, 2018, 14, 1931-1938.	1.4	9
21	Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice. Vaccine, 2021, 39, 4231-4237.	1.7	9
22	Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18â€“49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY). Open Forum Infectious Diseases, 2022, 9, ofab605.	0.4	9
23	Functional Evaluation and Genetic Evolution of Human T-Cell Responses After Vaccination With a Conditionally Replication-Defective Cytomegalovirus Vaccine. Journal of Infectious Diseases, 2021, 223, 2001-2012.	1.9	7
24	Matching-adjusted indirect comparison of pneumococcal vaccines V114 and PCV20. Expert Review of Vaccines, 2022, 21, 115-123.	2.0	7
25	Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes. Human Vaccines and Immunotherapeutics, 2016, 12, 2135-2141.	1.4	5
26	Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged â‰¥50Âyears: A randomized phase 3 trial (PNEU-TRUE). Vaccine, 2022, 40, 1342-1351.	1.7	5